Galectin-3 mediates the effect of PDGF on pulmonary arterial hypertension

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 9, 2015, Pages 15302-15307

  Guo, Shaomei ^a,b   Feng, Ziming ^a,b  

^a JIANGXI MEDICAL COLLEGE   (China)

^b Jiangxi Provincial People's Hospital   (China)

Author keywords

Galectin 3; Platelet derived growth factor; Pulmonary arterial hypertension

Indexed keywords

BETA ACTIN; GALECTIN 3; PLATELET DERIVED GROWTH FACTOR; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; FILTERS AND MEMBRANES; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROPLATE READER; MTT ASSAY; PATHOGENESIS; PROTEIN EXPRESSION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; WESTERN BLOTTING;

EID: 84946615690     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
3. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S and Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
4. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE and McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012; 142: 448-456.
5. Funasaka T, Raz A and Nangia-Makker P. Galectin-3 in angiogenesis and metastasis. Glycobiology 2014; 24: 886-891.
6. Yang RY and Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003; 60: 267-276.
7. Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T and Sato S. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 2012; 39: 539-544.
8. Fenster BE, Lasalvia L, Schroeder JD, Smyser J, Silveira LJ, Buckner JK and Brown KK. Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart Vessels 2015; [Epub ahead of print].
9. Short AD, Bian J, Ghosh TK, Waldron RT, Rybak SL and Gill DL. Intracellular Ca2+ pool content is linked to control of cell growth. Proc Natl Acad Sci U S A 1993; 90: 4986-4990.
10. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 2001; 81: 999-1030.
11. Berg JT, Breen EC, Fu Z, Mathieu-Costello O and West JB. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-B in lung parenchyma. Am J Respir Crit Care Med 1998; 158: 1920-1928.
12. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, Capron F, Galanaud P, Duroux P, Simonneau G and Emilie D. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11: 554-559.
13. Stenmark KR and Mecham RP. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997; 59: 89- 144.
14. Tanabe Y, Saito M, Ueno A, Nakamura M, Takeishi K and Nakayama K. Mechanical stretch augments PDGF receptor beta expression and protein tyrosine phosphorylation in pulmonary artery tissue and smooth muscle cells. Mol Cell Biochem 2000; 215: 103-113.
15. Voelkel NF and Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
16. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, Hirashima M and Liu FT. Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol 2000; 165: 2156-2164.
17. Dagher SF, Wang JL and Patterson RJ. Identification of galectin-3 as a factor in premRNA splicing. Proc Natl Acad Sci U S A 1995; 92: 1213-1217.
18. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT and Iacobelli S. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002; 23: 313-320.
19. Zou J, Glinsky VV, Landon LA, Matthews L and Deutscher SL. Peptides specific to the galectin- 3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion. Carcinogenesis 2005; 26: 309-318.
20. Yang RY, Hsu DK and Liu FT. Expression of galectin- 3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 1996; 93: 6737- 6742.
21. Ochieng J, Furtak V and Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004; 19: 527-535.
22. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A and Bergeron MG. Role of galectin- 3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 2002; 168: 1813-1822.
23. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J and Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172: 288-298.
24. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ and Sethi T. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006; 103: 5060- 5065.
25. Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Küpper I, Becker C, Ott S, Nusser P, Yamamura K, Rechtsteiner G, Warger T, Pautz A, Kleinert H, Schmidt A, Pieske B, Wenzel P, Münzel T and Löhler J. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 2007; 171: 463-472.
26. Bošnjak I, Selthofer-Relatić K and Včev A. Prognostic value of galectin-3 in patients with heart failure. Dis Markers 2015; 2015: 690205.
27. Yamboliev IA and Gerthoffer WT. Modulatory role of ERK MAPK-caldesmon pathway in PDGF-stimulated migration of cultured pulmonary artery SMCs. Am J Physiol Cell Physiol 2001; 280: C1680-C1688.
28. Katayose D, Ohe M, Yamauchi K, Ogata M, Shirato K, Fujita H, Shibahara S and Takishima T. Increased expression of PDGF A- and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 1993; 264: L100-L106.
29. Hassoun PM, Mouthon L, Barberà JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX and Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54: S10-S19.
30. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX and Weir EK. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S20-S31.
31. Cowan KN, Jones PL and Rabinovitch M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin- C, and smooth muscle cell apoptosis. Circ Res 1999; 84: 1223-1233.
32. Zhang S, Fantozzi I, Tigno DD, Yi ES, Platoshyn O, Thistlethwaite PA, Kriett JM, Yung G, Rubin LJ and Yuan JX. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2003; 285: L740-L754.